212 related articles for article (PubMed ID: 32805623)
1. Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit.
Vlot EA; Van den Dool EJ; Hackeng CM; Sohne M; Noordzij PG; Van Dongen EPA
Thromb Res; 2020 Dec; 196():1-3. PubMed ID: 32805623
[TBL] [Abstract][Full Text] [Related]
2. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
3. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
5. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring.
Susen S; Tacquard CA; Godon A; Mansour A; Garrigue D; Nguyen P; Godier A; Testa S; Levy JH; Albaladejo P; Gruel Y;
Crit Care; 2020 Jun; 24(1):364. PubMed ID: 32560658
[TBL] [Abstract][Full Text] [Related]
6. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK
J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346
[TBL] [Abstract][Full Text] [Related]
7. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
[TBL] [Abstract][Full Text] [Related]
8. Platelets are dominant contributors to hypercoagulability after injury.
Harr JN; Moore EE; Chin TL; Ghasabyan A; Gonzalez E; Wohlauer MV; Banerjee A; Silliman CC; Sauaia A
J Trauma Acute Care Surg; 2013 Mar; 74(3):756-62; discussion 762-5. PubMed ID: 23425732
[TBL] [Abstract][Full Text] [Related]
9. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
10. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications.
Voicu S; Delrue M; Chousterman BG; Stépanian A; Bonnin P; Malissin I; Deye N; Neuwirth M; Ketfi C; Mebazaa A; Siguret V; Mégarbane B
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9161-9168. PubMed ID: 32965009
[TBL] [Abstract][Full Text] [Related]
11. Coagulopathy in COVID-19: Manifestations and management.
Mucha SR; Dugar S; McCrae K; Joseph D; Bartholomew J; Sacha GL; Militello M
Cleve Clin J Med; 2020 Jul; 87(8):461-468. PubMed ID: 32409435
[TBL] [Abstract][Full Text] [Related]
12. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Helms J; Tacquard C; Severac F; Leonard-Lorant I; Ohana M; Delabranche X; Merdji H; Clere-Jehl R; Schenck M; Fagot Gandet F; Fafi-Kremer S; Castelain V; Schneider F; Grunebaum L; Anglés-Cano E; Sattler L; Mertes PM; Meziani F;
Intensive Care Med; 2020 Jun; 46(6):1089-1098. PubMed ID: 32367170
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.
White D; MacDonald S; Edwards T; Bridgeman C; Hayman M; Sharp M; Cox-Morton S; Duff E; Mahajan S; Moore C; Kirk M; Williams R; Besser M; Thomas W
Int J Lab Hematol; 2021 Feb; 43(1):123-130. PubMed ID: 32892505
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Romano LGR; Hunfeld NGM; Kruip MJHA; Endeman H; Preijers T
Br J Clin Pharmacol; 2023 May; 89(5):1617-1628. PubMed ID: 36495312
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: coagulation disorders and anticoagulant treatment in patients hospitalised in ICU.
Pluta J; Cieniewicz A; Trzebicki J
Anaesthesiol Intensive Ther; 2021; 53(2):153-161. PubMed ID: 34006056
[TBL] [Abstract][Full Text] [Related]
17. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
18. Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
Eck RJ; van de Leur JJCM; Wiersema R; Cox EGM; Bult W; Spanjersberg AJ; van der Horst ICC; Lukens MV; Gans ROB; Meijer K; Keus F
Sci Rep; 2022 Oct; 12(1):17408. PubMed ID: 36257974
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of coagulation status using viscoelastic testing in intensive care patients with coronavirus disease 2019 (COVID-19): An observational point prevalence cohort study.
Collett LW; Gluck S; Strickland RM; Reddi BJ
Aust Crit Care; 2021 Mar; 34(2):155-159. PubMed ID: 32773357
[TBL] [Abstract][Full Text] [Related]
20. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients.
Eriksson O; Hultström M; Persson B; Lipcsey M; Ekdahl KN; Nilsson B; Frithiof R
Thromb Haemost; 2020 Dec; 120(12):1720-1724. PubMed ID: 32871607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
